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Abstract
Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, 
particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed 
at the Upjohn Company in the 1970s and 1980s is presented.
Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug 
user fora discussion threads have been used to track their emergence as substances of abuse.
Results In terms of impact on drug markets, prevalence and harm, the most significant compound of this class to date has 
been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short-
lasting euphoric effects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related 
compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs 
market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol 
appears to be increasing and should be closely monitored.
Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and 
allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments. Pre-emptive 
research on the most likely compounds to emerge next, so providing drug metabolism and pharmacokinetic data to ensure 
that new substances are detected early in toxicological samples is recommended. As these compounds are chiral compounds 
and stereochemistry has a large effect on their potency, it is recommended that detection methods consider the determination 
of configuration.
Keywords Novel synthetic opioids · Psychoactive substances · U-drugs · Bromadol · Clinical and forensic toxicology
Introduction
Novel psychoactive substances (NPS) are continually evolv-
ing and emerging onto the illicit drugs market; however, 
the rate of emergence appears to be slowing down. Many 
compounds appear and disappear rapidly and it is challeng-
ing to attempt to carry out detailed research on all of them. 
It is, therefore, necessary to take a risk assessment and harm 
reduction based approach to focus on those substances with 
the greatest prevalence and propensity for harm. Materials 
containing fentanyl and fentanils (fentanyl analogues) are 
considered by many the greatest concern due to their preva-
lence, potency and diversity [1–3]. There are also other non-
fentanil novel synthetic opioids (NSOs) emerging across the 
illicit synthetic drug market, which adapt and diversify in 
a manner that is responsive to developments in the illicit 
drug supply chain and the new national and international 
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legislation designed to disrupt them [4]. Many of these 
NSOs are currently, or have previously been, present on the 
illicit market and have appeared in drug seizure casework 
or have been detected in body fluids submitted to clinical 
or forensic toxicology laboratories, albeit with low preva-
lence [5]. Some are being openly discussed on drug user fora 
and are available for sale on darkweb or clearweb vendor 
sites [6–8] and may not have been detected within foren-
sic and clinical samples [9, 10]. Many of these substances 
were originally developed as potential research targets in 
the pharmaceutical industry, their synthesis routes published 
and patented, and their pharmacological properties studied 
using the methodologies available at the time [11–23]. In 
most, if not all, cases their development was halted before 
clinical trials were carried out, often due to the presence 
of unwanted pharmacological side effects. Their emergence 
onto the illicit drug market is actively and effectively tracked 
by national and international early warning systems such as 
the European Monitoring Centre for Drugs and Drug Abuse 
(EMCDDA) early warning system (EWS) and this coordi-
nation ensures vital and rapid information sharing and risk 
assessment [24].
This review focusses on a sub-group of NSOs known col-
loquially as the “U-compounds” or “U-drugs”. These sub-
stances were originally synthesized in the 1970s and 1980s 
by the Upjohn Company, a pharmaceutical company from 
Kalamazoo, MI, USA and the review takes in other related 
compounds synthesized around the same time within the 
company and by other research teams [11–23].
The Upjohn Company, along with many other pharma-
ceutical companies at the time, were attempting to find a 
non-addictive opioid analgesic that did not cause respira-
tory depression or dependency, with a similar potency to 
morphine, a global search which continues to this day. This 
work, although not producing commercially viable opioid 
analgesics at the time, produced potent and, in some cases, 
highly selective opioid receptor agonists that have helped 
to unravel the mode of action and specific opioid receptor 
binding properties of the opioid family of drugs.
A pattern of the emergence of these substances onto the 
illicit drugs market has become apparent in recent years. 
Early papers and patents are scoured for compounds of inter-
est; identified substances (or closely related compounds 
with small structural alterations) then appear for sale on 
vendor sites, often marketed as “legal” alternatives to now 
controlled substances; the substances are either provided 
as free samples to buyers of other substances or purchased 
directly by users (who are often referred to as “psycho-
nauts”) and their effects discussed and reviewed in online 
drug user fora. The most prevalent of these non-fentanil 
NSOs so far has undoubtedly been U-47700 (trans-3,4-di-
chloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenza-
mide), described by users as giving rise to highly desirable, 
apparently short-lived euphoric effects creating a desire to 
redose [25]. U-47700 has recently been controlled at the 
national and international level, most notably in China [26, 
27], and so the illicit market appears to be seeking alterna-
tive compounds to appeal to users of U-47700.
It is difficult to predict which compounds may appear 
on the illicit drug market and which, if any, will become 
popular with users and/or gain a more substantial foothold 
in the mainstream illicit drug market. Now that U-47700 is 
internationally controlled and production and export from 
China is prohibited, some users will be seeking a “legal” 
alternative to other controlled opioids with a lower potency 
than the fentanils, whilst others may be seeking a substance 
which mimics the effects of U-47700 irrespective of its legal 
status. The laboratories synthesising the drugs will look to 
past structure activity relationship (SAR) studies, structural 
adaptations that appeared successful with other unrelated 
drugs classes or to those analogues which are the easiest 
and cheapest to produce due the availability of precursor 
compounds and the ease of synthesis.
Many jurisdictions react in a responsive way to the 
appearance of such novel substances on the illicit drugs 
market rather than in a pre-emptive or predictive manner. 
In doing so they could inadvertently be driving the struc-
tural diversification of the substances appearing on the illicit 
market.
Licit drug development: evolution 
of the N‑substituted benzamide analgesics 
and related compounds
Allen and Hanburys Limited compounds 
(AH‑compounds)
The antinociceptive effects of the N-substituted cyclo-
methylbenzamides were explored by Brittain et al. [17] at 
the United Kingdom pharmaceutical company, Allen and 
Hanburys Limited, in collaboration with the University of 
Aston, Birmingham, UK. The company had been acquired 
by Glaxo in 1958, but retained its name until 1978 after 
which it was subsumed into Glaxo Group Research Ltd. A 
series of compounds were synthesized and tested in vivo in 
mice. Harper et al. [11] published details of the synthesis 
of a series of 60 cyclohexyl derivatives (1-(3,4-dichloro-
benzamidomethyl)cyclohexyl-dimethylamines). Thirty-
five of these were subjected to preliminary pharmaco-
logical screening. Tests were carried out at oral doses of 
100 mg/kg (behaviour, body temperature, antimaximal 
electroshock, antagonism of leptazol-induced convulsions, 
and effects on phenylquinone-induced writhing); oral 
doses of 50 mg/kg (tremor, hypothermia); and a subcutane-
ous dose of 100 mg/kg (hot-plate effects observed directly 
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and on interaction with morphine). The N-substituted ben-
zamide derivatives, identified as compounds 51-53, 57 and 
58 in the paper [11], some of which were also reported in 
the Brittain et al. paper referred to using their “AH” codes 
[17], were identified as the most promising compounds 
(see Fig. 1 for the generic structure and Table 1 for struc-
tural details). One compound in particular, 3,4-dichloro-N-
[1-(dimethylamino)-cyclohexyl]methylbenzamide, named 
AH-7921, was identified as having the greatest analgesic 
properties, approximately 0.8 times that of morphine in 
comparative studies, and was selected for further acute 
animal studies. This work, including detailed synthesis 
methods, was submitted as a United States patent in 1974, 
assigned to Allen and Hanburys Limited, the patent being 
granted in 1976 [28]. During these studies, there was evi-
dence of the addictive potential of AH-7921, with physical 
dependence observed in the animals tested and so trials 
were discontinued at that time [17]. Further animal test-
ing was carried out by the Glaxo Group Research Ltd, 
later confirming that undesirable effects (e.g. Straub tail 
response, hypothermia, sedation, respiratory depression 
and inhibition of gastrointestinal propulsion) occurred 
at concentrations similar to those required for analgesia 
confirming that this compound should not be selected for 
further study [29].
Fig. 1  Allen and Hanburys Limited candidate opioid analgesic com-
pounds generic structure
Table 1  Identification and 
structural features of selected 
opioid analgesics developed by 
Allan and Hanburys Limited
    
Compound ID a Compound ID b Aromatic substitution c R c
    
AH-7563 51 -  N(CH3)2
AH-8529 52 4= Cl N(CH3)2
AH-8507 - 3= Cl 
4= Cl 
AH-8533 - 2= Cl  N(CH3)2
AH-7921 53 3= Cl 
4= Cl 
N(CH3)2
AH-8532 - 3= Cl N(CH3)2
AH-7959 56 3= Cl 
4= Cl 
- 57 2= Cl 
- 58 -
a As identified in [17]
b As identified in [11]
c Refer to Fig. 1 for the generic molecular structure for these analogues
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Upjohn Company compounds (U‑compounds 
or U‑drugs)
N-Substituted benzamides and acetamides From 1973, 
chemists at the Upjohn Company synthesized a series of 
N-(2-aminocycloaliphatic)benzamide compounds leading, in 
1975, to the discovery of the selective kappa-opioid recep-
tor (KOR) agonist, U-50488 (trans-2-(3,4-dichlorophenyl)-
N-methyl-N-(1S,2S)-2-(pyrrolidin-1-yl)cyclohexyl)-aceta-
mide), Fig. 2. The (−) trans-(1S,2S) isomer, also referred 
to as U-50488H, had greater affinity for KOR than the (+) 
trans-(1R,2R) or either of the cis-configurations or the (±) 
trans-racemic mixture, highlighting the need to take into 
account the important effect of stereochemistry on their 
pharmacological behaviour [15]. A large number of related 
compounds were patented in 1978 [12] and further related 
patents followed [e.g. 30, 31]. Information on some of these 
compounds is provided in Table 2. A number of different 
methodologies to determine in vitro opioid receptor binding 
affinity (KD) have been used in the cited literature and care 
should be taken when comparing such data directly between 
studies. Perhaps a more useful measure of comparison 
between studies is the relative affinity of the test compound 
to the different opioid receptors. Binding affinity to a target 
receptor is of itself not a direct measure of “potency” and 
such methods do not take into account off-target pharma-
cological effects which may affect downstream biological 
effects and toxicity.
A detailed description of U-50488H was first published 
in the peer reviewed literature in 1982 [18, 19]. It did not 
cause respiratory depression and was not habit-forming, but 
was found to cause sedation, diuresis and dysphoria, the lat-
ter properties being undesirable in medicinal products and 
indicative of KOR-mediated effects. The (−) trans-(1S,2S) 
U-50488 (U-50488H) and the (±) trans-racemic mixture are 
commercially available as reagents from specialist chemi-
cal supply companies (e.g. Merck, Tocris Bioscience, Axon 
Medchem etc.) and are widely used as model KOR agonists 
in experimental studies [15]. The discovery and deconvolu-
tion of the structure activity relationships of U-50488H, and 
its related compounds, including the important role of ste-
reochemistry in agonist activity, was elegantly described by 
the Upjohn chemist responsible for its development, Jacob 
Szmuszkovicz [15]. The generic structure of the N-substi-
tuted benzamides and acetamides is shown in Fig. 2a. The 
structural requirements for a potent KOR agonist appear to 
be a combination of the following: (1) a (−) trans-(1S,2S) 
configuration; (2) the presence of an N-methyl group on the 
nitrogen adjacent to the carbonyl and (3) the presence of a 
methylene  (CH2) “spacer” [15]. This is further illustrated by 
the modifications of the U-50488H structure which lead to 
the synthesis of two further highly selective KOR agonists 
with a (−) trans-(1S,2S) configuration; U-62066 (spira-
doline, 2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-
pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide) and 
U-69593 (N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-
1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide) both of which 
have a heterocyclic ring structure fused to the cyclohexyl 
moiety in the  R3 position (Fig. 2a, Table 1) [20–22].
The properties of U-50488H were compared to 
those of the assumed novel mu-opioid (MOR) ago-
nists U-47109 (3,4-dichloro-N-(2-(dimethylamino)
Fig. 2  Upjohn Company 
N-substituted benzamides and 
acetamides (U-drugs); a generic 
structure, b (+) trans-U-50488; 
2-(3,4-dichlorophenyl)-
N-methyl-N-((1R,2R)-2-
(pyrrolidin-1-yl)cyclohexyl)
acetamide, c (−) trans-U-50488, 
also known as U-50488H; 
2-(3,4-dichlorophenyl)-N-me-
thyl-N-((1S,2S)-2-(pyrrolidin-
1-yl)cyclohexyl)acetamide, 
d (+) trans-U-47700; 
(3,4-dichloro-N-((1R,2R)-2-
(dimethylamino)cyclohexyl)-
N-methylbenzamide)
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cyclohexyl)benzamide),  U-47700 and U-51754 
(2 - (3 ,4 -d i ch lo rophenyl ) -N - [2 - (d imet hylamino)
cyclohexyl]-N-methyl-acetamide) (Fig. 2) to demonstrate 
the drug’s selectivity for the KOR [13]. In this study, 
U-47700, which has a (+) trans-(1R,2R) configuration 
(and it is assumed U-47109 and U-51754 also have the 
same configuration), was found to have 7.5, eight and three 
times greater analgesic effect than morphine in antinoci-
ceptive tests (tail flick, tail pinch and hydrochloric acid 
writhing respectively). U-50488H, U-51754 and U-47109 
were found to be less potent than morphine, but still had 
measurable analgesic effects [13]. Characteristic MOR 
mediated effects (Straub tail, arched back, increased loco-
motor activity) were observed when mice were treated 
with U-47700, U-51754 and U-47109 but were not 
observed for U-50488H.
Further deconvolution of the “U-drug” structure activity 
relationships to MOR and KOR was reported in 1988 [14]. 
The removal of a chlorine atom in the meta-position on 
the phenyl moiety of U-47700 to give U-48520 (4-chloro-
N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide) 
leads to an apparent decrease in MOR affinity and further 
removing the chlorine in the para-position and replacing 
it with a hydroxyl group leads to a complete loss of affin-
ity to both MOR and KOR (Table 2). The presence of 
the methylene bridge in the structure appears to decrease 
affinity to MOR and increase affinity to KOR (Table 2).
Table 2  Identification, structural features and pharmacological data of selected N-substituted benzamides and acetamide opioid analgesics (col-
loquially known as U-drugs’) developed by the Upjohn Company
Compound ID 
First
reported licit 
development  
Reported 
illicit use 
Structural featuresa Reported opioid receptor binding affinities (nM)  
RefAromatic 
substitution 
(CH2)n
n =
R1 R2 R3 MOR  
KD (nM) 
± SEM 
KOR 
KD (nM) 
± SEM 
DOR 
KD (nM) 
± SEM 
Ratio  
MOR/KOR 
U-50488 
(compound 9)b
1982 2017/18       3 = Cl 
 4 = Cl 
1 CH3 H 430 2.2 n.a 195 [14] 
U-62066 
(spiradoline) 
1988 n.a 3= Cl 
4= Cl 
1 CH3 210 2.5 n.a 84 [14] 
U-69593 1985 n.a 1 CH3 1,700 
4,600 
7.2 
9.5 
n.a 236 
484 
[14] 
[20] 
U-51754 
Methene-U47700 
(compound  8)b
1982 2016 3= Cl 
4= Cl 
1 CH3 N(H3)2 H 220 71 n.a 3.10 [14] 
U-48800 n.a 2017 2= Cl 
4= Cl 
1 CH3 N(CH3)2 H n.a n.a n.a n.a n.a 
U-47700 
(compound 7)b
1982 2014 3= Cl 
4= Cl 
0 CH3 N(CH3)2 H 5.3 
57+21d
0.91±0.11d
910 
653+/-163d
110±11d
1105 ± 223d
480±110d
0.006 
0.087 
0.008 
[14] 
[32] 
[49]e
U-47109 
(compound  6)b
1982 n.a 3= Cl 
4= Cl 
0 H N(CH3)2 H 59 910 n.a 0.065 [14] 
U-48520 1988 n.a       4= Cl 0 CH3 N(CH3)2 H 200 2,900 n.a 0.069 [14] 
U-77891 
(compound  28)c
1983 2017 3= Br 
4= Br 
0 CH3 H 2 2300 105 0.008 [31] 
compound  29c
1989 n.a 3= Br 
4= Br 
0 CH3 H 6.3 >10,000 309 <0.001 [31] 
compound  31c 1989 n.a 2= Cl 
4= Br 
0 CH3 H 16 9000 >10,000 0.002 [31] 
U-49900 n.a 2016 3= Cl 
4= Cl 
0 CH3 N(CH2CH3)2 H n.a n.a n.a n.a n.a 
U-47931E / 
bromadoline 
n.a 2017 4= Br 0 H N(CH3)2 H n.a n.a n.a n.a n.a 
3,4-methylendioxy-
U-47700 
n.a 2017/18 3,4-
methylenedi-
oxy 
0 CH3 N(CH3)2 H n.a n.a n.a n.a n.a 
Isopropyl-U-47700 n.a 2018 3= Cl 
4= Cl 
0 C3H7 N(CH3)2 H n.a n.a n.a n.a n.a 
MOR, KOR and DOR refer to the μ-, κ- and δ-opioid receptors respectively
n.a data not available, SEM standard error of the mean, KD dissociation constant/ligand-receptor affinity
a Refer to Fig. 2a for the generic molecular structure
b Refers to compound identification in [12]
c Refers to compound identification in [31]
d In vitro receptor binding data provided is the inhibition constant (Ki) rather than KD [31]
e Data from Janowsky (2016) as cited in [49, 50]
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Opioid receptor binding profiles and the antinocicep-
tive properties of further related compounds were investi-
gated in 1989 by Fujimoto et al. [32] including U-77891 
(trans-3,4-dibromo-N-methyl-N-[1-methyl-1-azaspiro[4.5]
decan-6-yl]benzamide) (Table 2). This compound was first 
described in an Upjohn Company patent from 1985 [30] and 
is an N-substituted tertiary amide containing a heterocyclic 
ring structure on the cyclohexyl moiety, an N-methyl group 
adjacent to the carbonyl and halogen atoms in the 3,4-posi-
tions of the aromatic ring (bromines instead of chlorines 
of U-50488/U-47700), but unlike U-50488 and U-51754 
no methylene spacer is present. Other closely related ana-
logues (referred to as compounds 29-32 in the paper) are 
also described. The lack of the methylene spacer (and pos-
sibly a (+) trans-(1R, 2R) configuration—although this is 
not specifically mentioned) in the structures of U-77891 and 
compounds 29-32 appears to produce highly selective MOR 
agonists. The presence of halogens in the 3,4-position of the 
aromatic ring appears to enhance activity and is likely to 
protect the aromatic moiety from enzymatic hydroxylation 
once the substance is consumed. The selective MOR agonist 
properties of U-47700 were further confirmed in a more 
recent study [33]. Despite the development of a wide range 
of related compounds in later patents, U-47700 has remained 
one of the substances in this class with the greatest reported 
analgesic potency and greatest MOR binding.
4-Aminocyclohexanols Around the same time that the 
N-substituted benzamide and acetamide compounds were 
being developed at the Upjohn Company, a patent was filed 
in 1979 and published in 1982 for a series of 4-aminocy-
clohexanol compounds [34]. Trans-4-(p-Bromophenyl)-4-
(dimethylamino)-1-phenethylcyclohexanol, referred to sim-
ply as “compound 1” in the original research paper (BDPC, 
also referred to as bromadol in online drug user discussion 
fora and vendor sites) was found to be a highly potent anal-
gesic in animal studies (tail flick, tail pinch, hydrochloric 
acid writhing), effects that were reversed by naloxone, 
indicating that the analgesic activity was mediated via the 
MOR [35]. The trans isomer was determined to be consider-
ably more potent than the cis isomer (Fig. 3), the molecular 
structure being found to be superimposable upon the molec-
ular structure of the potent synthetic opioid fentanyl [35].
It was originally stated that BDPC/bromadol had 10,000 
times the analgesic potency of morphine in animal stud-
ies [34] although a more recent study, comparing analge-
sic potency using a standard mouse hot plate assay where 
BDPC/bromadol was introduced by intraperitoneal injec-
tion, suggests that its analgesic potency may be lower, at 
around 500 times that of morphine and 2.9 times that of 
fentanyl [36]. BDPC/bromadol was the lead compound for 
a further series of 4-amino-4-arylcyclohexanone analogues 
and their derivatives prepared by the Upjohn team to provide 
structure activity relationship data [16, 37, 38]. None had 
analgesic properties greater than BDPC/bromadol, although 
a trans-chlorinated analogue showed similar potency as did 
an analogue where the phenethyl moiety was replaced with 
a cyclohex-3-ene moiety [37]. Another analogue of BDPC/
bromadol, trans-4-(p-bromophenyl)-4-(dimethylamino)-
1-(2-thiophen-2-yl-ethyl)-cyclohexanol (C8813, thiobro-
madol Fig. 3.) was synthesized and characterized in 2003 
[36]. This work was the first to study receptor binding affini-
ties for both BDPC/bromadol (Ki = 1.49 nM for MOR) and 
C8813 (Ki = 1.37, 3.24 and > 1000 nM for MOR, DOR and 
KOR respectively). The antinociceptive potency observed 
previously and in the same study is perhaps greater than 
that expected given the opioid receptor binding affinity 
data presented and so warrants further detailed study. As 
far as the authors are aware, none of these substances have 
been subject to clinical trials and none have been developed 
commercially, although a method for the purification of 
BDPC/bromadol after synthesis was published by a Chinese 
research team in 2014 and refers to a “commercially avail-
able bromadol” solution bought from a Chinese vendor [39].
Fig. 3  Aminocyclohexanol 
based analgesics a BDPC/bro-
madol and b C8813
(a) (b)
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The appearance of non‑fentanil novel 
synthetic opioids on illicit drug markets
The first non-fentanil novel synthetic opioid to appear 
on illicit markets was the opioid analgesic, AH-7921 
around 2012–13 (Fig. 4a), subsequently controlled inter-
nationally in 2014 and in the UK in 2015 as a Class A 
drug under the Misuse of Drugs Act [40–42]. A structur-
ally unrelated compound, MT-45 (1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine, Fig. 4b), originally synthesized 
and studied in Japan in the 1970s as a candidate opioid 
analgesic, emerged and was controlled under the same 
legislation soon after [43–45]. A fluorinated analogue, 
2F-MT-45 (1-cyclohexyl-4-(1-(2-fluorophenyl)-2-pheny-
lethyl)piperazine) has recently been detected in the UK, 
however there is no evidence that the substance is avail-
able on vendor sites, possibly due to the unpopularity of 
MT-45 (and it’s recorded side effects) amongst users [46]. 
U-47700 (Fig. 2d), a structural isomer of AH-7921, was 
first detected in Europe in Sweden in late 2014. AH-7921, 
MT-45 and U-47700 have already been the subject of a 
number of detailed reviews and risk assessments [4, 5, 
41, 44, 47–54] and all have now been internationally 
controlled. U-47700 was made a Schedule 1 substance 
in the United States in November 2016 [55] and the UK 
controlled it as a Class A Schedule 1 substance under the 
Misuse of Drugs Act 1971 and Misuse of Drugs Regula-
tions 2001 in June 2017 [56]. China, widely agreed to 
be the main production site, banned its manufacture and 
export, along with MT-45, in July 2017 [27].
Since its appearance on the illicit drug market, U-47700 
has become one of the most prevalent non-fentanil NSOs, 
particularly in the United States, and case reports referring to 
the substance in drug seizures and toxicology cases continue 
to be published [57–76]. In Europe, U-47700 was reported to 
the EMCDDA EWS in January 2015 [77]. The reporting of 
the presence of U-47700 in products that users may naturally 
believe to contain a different class of drug is of particular 
concern. U-47700 was recently detected in plant/incense-
like products in Belgium, which would normally be expected 
to contain synthetic cannabinoid receptor agonists (SCRAs), 
colloquially known as “spice” [78]. In early 2016, U-47700 
was detected in approximately 3000 illicit tablets of at least 
four visually distinct types in Scotland, one of which was 
visually identical to those known to normally contain the 
benzodiazepine etizolam and two of which would likely be 
described as “street diazepam” by users, illicit tablets with 
a high prevalence in the illicit drug market in Scotland [79].
As a result of the international control of U-47700 and 
the ban on its manufacture in, and export from, China [27], 
it is perhaps predictable that U-47700 prevalence will in 
the future, or will have already, started to decline as has 
been previously observed for many, but not all, substances 
in the same situation. U-47700 analogues originating from, 
or adapted from compounds reported in the early literature, 
have started to appear on illicit drug market and a high state 
of vigilance and information sharing is maintained through 
international early warning systems. Summary structural 
information on the compounds emerging on to the illicit 
market is provided in Table 2.
U-49900 (3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-
N-methyl-benzamide) is a novel structural analogue of 
U-47700 (Table 2), first noted on “research chemical ven-
dors” websites and on online drug user fora in November 
2016 [80]. A test purchase and analytical characterization 
study was carried out by the European Union (EU) co-
funded RESPONSE project, run by the Slovenian National 
Forensic Laboratory in November 2016 [81], and soon 
after an alert was published by the EMCDDA EWS [82]. 
Unlike U-47700, for which at least limited early (and now 
updated) pharmacological data exist, no such data for this 
analogue are currently available. The chemical structure 
retains the majority of the key features that were identified 
by Loew et al. [14] as promoting MOR agonist mediated 
effects (3,4-dichloro on the phenyl ring, the lack of a meth-
ylene spacer and an N-methyl group adjacent to the car-
bonyl), but with N-diethyl substitution on the cyclohexyl 
moiety instead of the N-dimethyl substitution of U-47700 
(Table 2). Fabregat-Safont et al. [83] identified and analyti-
cally characterized U-49900 in great detail using a drug sam-
ple seized in Spain. In addition, a monograph on U-49900 
was recently published by the Scientific Working Group on 
Fig. 4  Internationally controlled 
non-fentanil novel synthetic opi-
oids a AH-7921 and b MT-45
(a) (b)
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Drugs (SWGDRUG) [84]. U-49900 has since been reported 
in seizures and toxicological samples in the United States. 
Krotulski et al. [85] describe the identification of U-49900 
in post-mortem blood and urine specimens collected after 
an apparent drug overdose and U-49900 detection has also 
been reported in seized drug samples by the United States 
Drug Enforcement Administration (DEA) [86].
U-51754 was described in the original Upjohn Company 
patents and related studies [12–14] and has recently appeared 
on illicit drug vendor sites listed as both methene-U-47700 
(most likely named as such due to the presence of the meth-
ylene spacer and to illustrate its relationship to U-47700 for 
marketing purposes) and U-51754 (see Table 2). U-51754 
was first detected in Europe via a test purchased sample 
received by the RESPONSE project in October 2016. The 
sample was analysed and reported in January 2017 [87] 
and the data shared via the EMCDDA EWS [88]. U-48800 
(2-(2,4-dichlorophenyl)-N-(2-(dimethylamino)cyclohexyl)-
N-methyl-acetamide), differing from U-51754 only in the 
positions of one of the chlorine atoms on the phenyl moiety 
(Table 2), was not included in the original Upjohn Com-
pany patents or any of the related pharmacological studies. 
U-48800 was detected in Germany in a sample received for 
testing in October 2017 by the ADEBAR project, a project 
co-funded by the Internal Security Fund of the EU, the Ger-
man Federal Criminal Police Office, the German Federal 
Customs Service and a number of State Bureaus of Criminal 
Investigations. The data was reported to the RESPONSE 
project in February 2018 [89] and detection of U-48800 in 
seized samples was also notified by the DEA in the last quar-
ter of 2017 [86].
In early animal studies U-51754, was reported to be 
approximately ten times less potent as a MOR agonist (and 
therefore approximately 0.75 times the analgesic potency 
of morphine) than U-47700. It is likely to have more pro-
nounced KOR mediated effects [13] than U-47700 due to the 
presence of a methylene bridge in the molecular structure 
[14], a feature shared by U-48800 for which no in vitro or 
in vivo data are currently available.
U-77891 (Table 2) started to appear on user discussion 
fora in early 2016 [90] continuing into 2017 [91] although 
there are no available reports of users actually receiving or 
taking the substance. It has appeared on clearweb vendor 
sites, although there is no confirmation that it is actually 
being sold and to the best of the author’s knowledge no sei-
zures of this compound have been reported.
U-50488 (Table  2) has been commercially available 
from specialist chemical suppliers for some time and many 
research studies have utilised this model KOR agonist in 
experimental studies. The first reported illicit seizure in 
Europe was in Sweden in November 2017 and was reported 
to the EMCDDA EWS [92]. Analysis was carried out by 
the National Forensic Centre, Sweden and U-50488 was 
identified by comparison with a commercially available (±) 
trans isomer reference standard, although no determination 
of the stereochemistry of the U-50488 in the seized sample 
was carried out (Simon Dunne, National Forensic Centre, 
Linköping, Sweden, personal communication). As men-
tioned in the previous sections, the (−) trans-(1S,2S) isomer 
is a selective KOR agonist, whilst the (+) trans-(1R,2R) iso-
mer is a non-selective opioid receptor agonist with relatively 
poor affinity for both the MOR and KOR receptors [15].
U-47931E/bromadoline  ( trans-4-Bromo-N-[2-
(dimethylamino)cyclohexyl]-benzamide; Table 2) is a MOR 
agonist referred to in the original 1978 Upjohn Company 
patent [12] as example 10, with the name bromadoline 
being registered by the company in 1983 [93]. A 1985 study 
referred to bromadoline as a compound undergoing “clinical 
testings in humans for safety and efficiency” [94]. The paper 
refers to further studies being carried out on the disposi-
tion kinetics of bromadoline in humans and canines; how-
ever, apart from being included in a further study by Glaxo 
Group Research Ltd in 1987, the authors have been unable 
to find any further published studies on this compound [95]. 
Around September 2017, U-47931E/bromadoline appears to 
have started to be sold on web vendor sites and was identi-
fied for the first time in Europe by the RESPONSE project 
via a test purchased sample received in October 2017 from 
a web vendor [96]. The analytical data for the substance was 
reported in November 2017 and an EMCDDA EWS notifica-
tion was communicated soon after [97]. The stereochemistry 
of the sample was not determined and, as far as the authors 
are aware, no seizures have yet been reported in the pro-
fessional or peer-reviewed literature. A reference standard 
has been produced for the U47931E/bromadoline analogue 
N-methyl-U-47931 and is now commercially available [98], 
however, to the authors’ knowledge there is currently no 
indication that this compound has yet appeared on the illicit 
drugs market.
I sopropyl -U47700  ( t rans -3 ,4-d ichloro-N - [2-
(dimethylamino)cyclohexyl]-N-methyl-benzamide; Table 2) 
is one of the most recent U-drug analogues to appear on 
web vendor sites and was identified by the RESPONSE pro-
ject via a test purchased sample, received in January 2018 
[99]. To date the stereochemistry of the sample has not been 
determined and no European seizures have been reported in 
the open literature. Isopropyl-U47700 has been reported in 
toxicological samples from two cases submitted in March 
2018 in the United States in which 3,4-methylenedioxy-
U-47700 was also detected [9] and was reported for the first 
time in seizures in the DEA emerging threat report for the 
2nd quarter of 2018 [100].
3,4-Methylenedioxy-U-47700 (trans-N-2-(dimethylamino)
cyclohexyl)-N-methylbenzo[d] [1, 3] dioxole-5-carboxa-
mide; Table 2) is the latest compound of this series to be 
reported to the EMCDDA EWS having been detected in a 
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single sample seized in Poland in April 2018 [101]. The 
stereochemistry of the sample was not determined. The 
two chlorines in the 3, 4-position of the benzene ring have 
been replaced by a 3,4-methylenedioxy ring system, similar 
to that seen in a large number of psychoactive substances 
including substituted phenethylamines and cathinones. In 
early structure activity relationship studies for the N-substi-
tuted benzamides and acetamides, the removal of the chlo-
rine atoms in the 3,4-positions of the benzene ring led to a 
complete removal of MOR mediated effects however there 
is no information available on the effect on the pharmaco-
logical profile of such a structural alteration. There is no 
information on the pharmacological effects of this substance 
although the substance has been detected in five cases sub-
mitted from January 2018 in the United States, and in two of 
these, isopropyl-U47700 was also detected [9, 10].
BDPC/bromadol To the best of the authors’ knowledge, at 
the time of writing there has only been one report of a drug 
seizure involving BDPC/bromadol. The seizure was reported 
in Montreal, Canada in 2013, although analytical data con-
firming the presence of the drug or details of the amounts 
seized is not currently publicly available and therefore the 
report cannot be confirmed [102]. There are no publicly 
available reports of any seizures in Europe.
Online discussion forum based discussions 
of emerging U‑drugs and BDPC/bromadol
There are a number of drug-related internet fora and online 
drug user communities. The benefits and risks of the use of 
data from such fora for novel illicit drug research purposes 
have been discussed previously [103, 104]. When using 
such sites, users are generally seeking reports of drug use 
and experiential information and will also post self-reports 
on the characteristics of novel drugs and their subjective 
experiences with them. Previous studies have identified four 
main themes of the discussion threads on such fora where 
users sought (1) reliable information on novel and emerging 
substances, (2) dosage and administration information, (3) 
information on subjectively experienced effects of novel and 
emerging substances, and (4) support and safety information 
from other users [103]. Online communities such as this 
have been previously described as having a self-regulating 
approach to novel drugs appearing on the illicit market, rap-
idly sharing information on either harms associated with 
novel substances or if subjective effects are positive or nega-
tive. Researchers seeking information from such fora must 
acknowledge that the motivation for users to post informa-
tion about new substances cannot be verified and the actual 
substance taken by the user can also not be verified—a user 
may not have been sold the substance they believe they have 
been sold by a web vendor. In addition, researchers must be 
aware of the placebo effect with regards to a self-reported 
subjective experience; the fact that users may have used 
other substances before, during or after the substance under 
test; and as regular drug users, they are likely to have built 
up tolerances to, in this case, opioids which will affect their 
response to a particular substance. Nevertheless, some 
useful information can be obtained on the timeline of the 
appearance of new drugs on the market and users subjective 
experience of them. The information provided below gives 
examples of online discussion fora threads only and is not an 
exhaustive list of such discussions available online.
Online discussions on U-49900 have already been 
reported previously [83] and are not discussed in detail here. 
Postings referencing either U-51754 or its alternative name, 
methene-U-47700, began to appear between May and Sep-
tember 2016 indicating that the drug had appeared on web 
vendor sites. One user referred to U-51754 as an alterna-
tive to U-47700 after the latter had “become illegal” and 
predicted that it might be dysphoric rather than euphoric 
[105]. Another user reported taking the drug rectally and 
claimed the effects were strong, dysphoric and dissociative 
and with a relatively short duration of around 45 min [106]. 
Forum posts in another discussion thread, discuss the origi-
nal research published by the Upjohn Company [107]. Other 
users reported unpleasant dissociative experiences with no 
euphoria [108]. The reaction from forum users is generally 
negative and advice to avoid the substance has been com-
municated. Postings referencing U-48800 began to appear 
in April 2017 [109, 110]. In general, the response to this 
drug by users of online fora has been, as for U-51754, gen-
erally negative, although some posts have indicated a more 
positive, but mild experience [110]. User fora discussions of 
U-47931E/bromadoline started to appear around September 
2017 and appear to identify variability in the products sold 
as U-47931E/bromadoline on vendor websites and also indi-
cate that vendors were providing samples for testing with 
other purchases. In early posts, at least two distinct batches 
of the drug were discussed, one white in colour and one 
brown/tan. Detailed user reports for both batches describe 
distinct subjective user experience differences between the 
two [111, 112]. Insufflation of the brown/tan sample alleg-
edly produced a rush and euphoria whilst another user states 
that the subjective effects of U-47931e/bromadoline are 
milder than for U-47700, but last longer [113, 114].
Discussions relating to 3-4-methylenedioxy-U47700 
appeared in May and June 2017 [115, 116] and for isopro-
pyl-U-47700 appear to start around November and Decem-
ber 2017 with users stating the latter drug had been offered 
for sale on vendor sites [117, 118]. The user response to 
these substances appears almost uniformly negative.
BDPC/bromadol has been discussed on online user fora 
for many years [e.g. 119, 120]; however, substances purport-
ing to be BDPC/bromadol seem to have recently increased in 
prevalence on vendor sites (early to mid 2017). Since then a 
 Forensic Toxicology
1 3
number of experiential reports have been posted and a com-
mon theme of such user reports is the lack of the sought after 
euphoric effects [8, 121]. Some users posting on a German 
language forum have reported buying BDPC/bromadol as 
a purported 10 mg/mL solution [121]. Due to its reported 
analgesic potency in animal studies, its reported MOR affin-
ity, its appearance on vendor sites in a number of forms and 
the potential for harm, the prevalence of this compound in 
drug seizures and toxicological samples should be closely 
monitored.
It seems clear, at least from the limited information pro-
vided from drug user forum posts, that novel U-drug ana-
logues and BDPC/bromadol are appearing on web vendor 
sites, although they may appear and disappear over relatively 
short time periods based on availability and user demand or 
response. Their actual prevalence in casework and appear-
ance in biological samples is mostly unknown, but would be 
expected, at this time, to be very low. In general, the major-
ity of these compounds, in the reports available, have been 
viewed negatively relative to the user experiences relating 
to U-47700. Given an understanding of the structure activity 
relationships and known pharmacology of those U-drug ana-
logues that have been studied, this may be seen as not overly 
surprising. It will be interesting to observe if users will grow 
tired of trying these subjectively unpopular analogues or if 
they will continue to experiment with new analogues as they 
enter the market in the hope of a more subjectively positive 
user experience.
Toxicology, metabolism and toxicovigilance
When a drug is consumed it may or may not undergo bio-
transformation to more polar metabolites to aid its excre-
tion from the body and those metabolites may themselves 
be pharmacologically active. If biotransformation is rapid 
and exhaustive, it may be challenging for toxicologists to 
identify the parent drug in urine and blood samples, espe-
cially if the intoxication was not fatal and samples were 
taken a considerable time after drug ingestion. It is there-
fore important to understand metabolic processes includ-
ing actual and intrinsic drug clearance rates and metabo-
lite identification. This is especially true if analysts wish 
to preemptively scan for substances, and their postulated 
metabolites, that may enter the illicit drug market and may 
appear in biological matrices submitted to the toxicology 
laboratory for testing.
For U-47700, N-desmethyl-U-47700 and N,N-didesme-
thyl-U-47700 were identified both in in vitro assays using 
human liver microsomes (HLM) and casework samples 
as the main (major) metabolites of U-47700 with addi-
tional hydroxylation occurring at varying positions on the 
cyclohexyl moiety [59–62, 122].
For U-49900, N-desethyl-U-49900 and N,N-didese-
thyl-U-49900 were identified as the major metabolites, 
with, as for U-47700, N-dealkylation occurring on the 
N-cyclohexyl moiety, as well as minor metabolites with 
subsequent hydroxylation on the cyclohexyl ring. Unlike 
U-47700 N-demethylation also occurred subsequently on the 
nitrogen adjacent to the carbonyl. These metabolites were 
determined in vitro using HLM [122].
There are close structural similarities between the U-drug 
analogues entering the illicit drug market. From the data 
available for U-47700 and U-49900 it is possible to pre-
dict the metabolites formed from the novel substances dis-
cussed in this review. An early study on the metabolism of 
U-47931E/bromadoline appears to confirm this, with two 
metabolites proposed to be N-desmethyl-U-47931E and 
N,N-didesmethyl-U-47931E detected in blood, plasma and 
urine from human and canine samples [95]. It is recom-
mended that the pseudo-molecular ions of the parent drug 
and predicted metabolites for the novel non-fentanil syn-
thetic opioids discussed in this paper are incorporated into 
high resolution mass spectrometry screening methods in 
toxicology laboratories and that these are updated as and 
when in vitro and in vivo metabolite data become available.
A large number of studies have reported the identifica-
tion of U-47700 in toxicological samples and information 
on pharmacokinetics is starting to be published. Koch et al. 
[123] reported the analysis of samples from a patient who 
was admitted to hospital following the alleged smoking of 
an opioid. Serum and urine samples were taken and flu-
bromazepam, its metabolite hydroxyl-flubromazepam and 
U-47700 were detected. Serum samples were taken over a 
known time period and concentrations of U-47700 decreased 
exponentially from an initial serum concentration of 370 ng/
mL. The half-life of U-47700 in this patient was calculated 
to be approximately 6 h.
Concentrations of U-49900 in toxicological samples 
have only been reported in one casework sample to date 
which involved a fatal intoxication [85]. Postmortem blood 
and urine concentrations of U-49900 were found to be 1.5 
and 2.2 ng/mL, respectively, and tetrahydrofuranylfentanyl 
(399 ng/mL blood) and methoxy-phencyclidine (1.0 ng/mL 
blood) were also detected.
Studies on the bioavailability, pharmacokinetics and 
metabolism of BDPC/bromadol have yet to be published.
Legislative controls for non‑fentanil novel 
synthetic opioids
A number of jurisdictions are reacting to the appearance of 
new non-fentanil NSOs in the illicit drugs market. In the 
United States, U-47700 is a Schedule 1 substance under the 
Controlled Substances Act and therefore its analogues will 
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be controlled under the Controlled Substance Analogue Act 
of 1986. In July 2017, the state of North Carolina controlled 
U-47700, U-49900 and U-77891 under the State Synthetic 
Opioid and Other Dangerous Drugs Control Act [124]. In 
March 2018, the state of Minnesota added bromadol to 
schedule 1 of the controlled substances law [125]. Canada 
recently controlled U-47700 and “its salts, derivatives, iso-
mers and analogues, and salts of derivatives, isomers and 
analogues”, including U-47931E/bromadoline, U-47109, 
U-48520, U-50211 and U-77891 [126]. In addition, the leg-
islation controlled the precursor of U-47700, and many of its 
analogues, N1,N1,N2-trimethylcyclohexane-1,2-diamine and 
its salts. The precursor and synthetic route was described in 
the original Upjohn Company patents and related scientific 
papers, although other synthetic routes using alternative 
precursors are likely. In April 2018, Sweden brought into 
force a legislative ban on U-47931E/bromadoline to join 
AH-7921, MT-45 and U-47700 [127]. In Latvia, U-51754 
was controlled by the Center for Disease Prevention and 
Control in February 2017 [128]. In the UK, U-47700 is the 
only U-drug currently covered by the Misuse of Drugs Act 
1971 and the Misuse of Drugs Regulations (2001), whereas 
all other psychoactive analogues and the aminocyclohex-
anes would be controlled by the Psychoactive Substances 
Act 2016. In China, U-47700 is the only U-drug thus far to 
be controlled and so the production of analogues and fur-
ther market development may continue if there is seen to 
be a demand for such substances. The legislative controls 
introduced in China are highly impactful, greatly decreasing 
international availability of such substances and are to be 
commended. Controlling analogues of U-47700 and includ-
ing BDPC/bromadol in future drug control legislation may 
be an effective and pre-emptive response and may halt the 
diversification of such analogues entering the market cur-
rently and in future.
Predicting the next emerging U‑drugs 
on the illicit drugs market
The introduction of new U-drug analogues onto the illicit 
market has appeared, up to now, to be relatively haphazard 
with compounds deriving either from the original Upjohn 
Company patents and the related peer reviewed scientific 
literature (U-51754, U-47931E, U-77891, U-50488) or from 
untested structural adaptations of those original compounds 
(U-48800, U-49900, isopropyl-U47700, 3,4-methylenedi-
oxy-U47700). In general, these substances do not appear 
as prevalent as U-47700 has been and are generally poorly 
received, if reports on novel drug user fora are to be consid-
ered representative. As drugs with similar pharmacologi-
cal effects to U-47700 may continue to be sought, it should 
be considered a possibility that other analogues, aimed at 
preserving the key structural features of U-47700, e.g. pro-
moting selective MOR mediated effects, or alternatively 
new derivatives with little regard for the original structure 
activity relationships will appear on the illicit market. Some 
additional substances have recently been reported on ven-
dor sites, MPF-47,700 (advertised as a U-47700 analogue) 
and U-4TDP (advertised as being similar to U-51754) but 
these cannot be verified as novel substances as no chemical 
structures are provided and to date no web-sourced mate-
rials have been characterised or their chemical structures 
elucidated [129].
Conclusions
For all of the drugs reviewed, it is important that the effect 
of stereochemistry on their pharmacological profile is not 
underestimated. From a legal perspective this may be of little 
interest as the analyst must simply determine that a certain 
substance is present or not, and determine whether or not it 
is controlled under the relevant national and international 
legislation; however, it is important from a toxicological and 
harm reduction perspective. Such information is also likely 
to provide information on synthetic routes and precursor 
sources. Determination of stereochemistry is rarely, if ever, 
included in current standard analytical testing protocols for 
illicit drug seizures.
There is a requirement to determine the chemical struc-
tures of metabolites of new substances to ensure their timely 
detection in clinical and forensic toxicology casework, aid-
ing the monitoring of their emergence as substances of 
abuse. This is particularly true for BDPC/bromadol for 
which no published data currently exists. It is important to 
have a full understanding of what vendors and users seek to 
gain from the development of such novel illicit substances 
and as a result to pre-empt adverse events and/or predict 
new substances as, or before, they emerge. As a result, drug 
testing, clinical and forensic toxicology laboratories further 
increase the effectiveness of national and international moni-
toring systems. In our opinion, where there is a potential 
future risk, reference materials should continue to be syn-
thesized in both a responsive and pre-emptive manner; web-
sourced materials should be analytically characterized; their 
metabolism studied in vitro and the identity and pharmaco-
logical activity of parent drugs and metabolites elucidated.
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